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Abstract
While oxidative stress has been linked to Alzheimer’s disease, the underlying pathophysiological relationship is unclear. To
examine this relationship, we induced oxidative stress through the genetic ablation of one copy of mitochondrial
antioxidant superoxide dismutase 2 (Sod2) allele in mutant human amyloid precursor protein (hAPP) transgenic mice. The
brains of young (5–7 months of age) and old (25–30 months of age) mice with the four genotypes, wild-type (Sod2
+/+),
hemizygous Sod2 (Sod2
+/2), hAPP/wild-type (Sod2
+/+), and hAPP/hemizygous (Sod2
+/2) were examined to assess levels of
oxidative stress markers 4-hydroxy-2-nonenal and heme oxygenase-1. Sod2 reduction in young hAPP mice resulted in
significantly increased oxidative stress in the pyramidal neurons of the hippocampus. Interestingly, while differences
resulting from hAPP expression or Sod2 reduction were not apparent in the neurons in old mice, oxidative stress was
increased in astrocytes in old, but not young hAPP mice with either Sod2
+/+ or Sod2
+/2. Our study shows the specific
changes in oxidative stress and the causal relationship with the pathological progression of these mice. These results
suggest that the early neuronal susceptibility to oxidative stress in the hAPP/Sod2
+/2 mice may contribute to the
pathological and behavioral changes seen in this animal model.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative
disorder and the increase of oxidative stress has been linked to the
progression of the disease. Interestingly, transgenic mouse models
of AD also readily display increases in oxidative stress [1–3].
Specifically, the indicators of oxidative stress lipid peroxidation
and heme oxygenase-1 (HO-1) induction are found to be increased
in a transgenic mouse model overexpressing mutant amyloid-b
precursor protein (APP) [1]. While the role of amyloid-b (Ab)i n
AD development is supported by many studies [4], the long-
standing hypothesis that mitochondrial dysfunction and oxidative
stress also play fundamental roles in the disease has recently gained
experimental traction and renewed interest [5–8]. In fact,
oxidative damage is now recognized as one of the earliest changes
in both familial and sporadic forms of AD [9–11].
Superoxide dismutase 2 (Sod2) is an antioxidant enzyme which
detoxifies superoxide radicals within the mitochondrial matrix.
Mice that have disruptions in the Sod2 gene accumulate nucleic
acid oxidative damage in the brain [12] while fertility and lifespan
of these hemizygous Sod2+/2 and wild type animals are identical
[13,14]. Interestingly, combining the reduction of Sod2 activity
with hAPP transgenic mice accelerates several features of AD-like
pathology including behavioral changes and development of
cerebrovascular amyloidosis [15]. However, specific changes in
oxidative stress and the causal relationship with the pathological
progression of these mice has not been fully analyzed [15,16]. In
this study, therefore, we assessed the effect of Sod2 reduction in
this animal model of AD by measuring the extent of oxidative
stress in both young mice at 5–7 months of age, in which amyloid
deposition is not yet apparent, as well as in aged mice, at 25–30
months of age. Levels of the lipid peroxidation adduct 4-hydroxy-
2-nonenal (HNE) pyrrole and HO-1, which are increased during
periods of oxidative stress, were analyzed in the brains of old and
young mice. Parallel to the finding in AD where the level of HNE
and HO-1 is dramatically increased in the vulnerable neurons
[17,18], reduced Sod2 in mice overexpressing APP results in
significantly increased oxidative stress, most notably in younger
mice. Thus, reduced Sod2 activity together with mutant hAPP
overexpression increases oxidative stress and may facilitate the
disease progression and increase the severity of AD-like pathology
found in this APP transgenic mouse model.
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Transgenic mice
All the transgenic mouse strains used in this study (Sod2
+/+,
Sod2
+/2, hAPP/Sod2
+/+, and hAPP/Sod2
+/2) has been described
in the previous study [19]. All protocols involving the use of mice
were approved by the Institutional Animal Care and Use
Committee of the University of California, San Francisco.
Immunohistochemical analyses
For immunohistochemical analysis, 8 mm paraffin-embedded
sections from the brains of 26 young mice (5–7 months of age;
n=627 per group) and 20 old mice (25–30 months of age;
n=426 per group) were prepared and blinded for the analysis. All
experiments were carried out by an experimenter blinded to
genotype. Slides of all mice were immunostained simultaneously
under identical conditions, using the peroxidase-anti-peroxidase
method. Initially, slides were deparaffinized in xylene and then
transferred through a graded ethanol series followed by incubation
in Tris-buffered saline (50 mM Tris, 150 mM NaCl, pH=7.6,
TBS) to rehydrate the tissue. Subsequently, the tissues were
incubated overnight with the primary antibodies directed against
HNE-pyrrole [17], HO-1 [18], GFAP (Zymed Laboratories). The
following day, species-specific secondary antibodies and PAP
complex were applied, then the slides were rinsed in Tris buffer
and developed for 5 minutes with the chromagen 39-39-diamino-
benzadine (Dako) as previously described [20]. Finally the slides
were dehydrated, mounted with a coverslip and analyzed.
For double immunohistochemistry, the brain sections were
incubated overnight at 4uC with anti-HO-1 rabbit antibody or
anti- HNE pyrrole rabbit antibody in addition to anti-GFAP
mouse monoclonal antibody. Alexa Fluor 488- and 568-coupled
secondary antibodies (Invitrogen, Carlsbad, CA) were used for
detection. Images were acquired through an AxioCam camera on
an Axiovert 200 M microscope (Zeiss, Thornwood, NY). Images
were then analyzed with the Axiovision software (Zeiss).
Image analysis
Quantitative analysis of the neuronal accumulations of the
oxidative stress markers HNE and HO-1 was performed using
Axiovision image analysis software (Zeiss). Images of the entire
hippocampus were prepared and all neurons of the CA1 and CA2
regions were analyzed and their relative densitometric values,
minus the mean level of the surrounding neuropil, were
determined. The mean neuronal staining levels for each mouse
were calculated. The data was then decoded and the values for all
the mice in the different genotype groups were averaged, and
statistical significance of differences between the means was
determined with one-way ANOVA or student’s t-test.
Results
In young mice (5–7 months), we compared the accumulation of
the oxidative stress markers in the brain of mice representing the 4
different genotypes. Genotype-dependent differences in neuronal
levels of the HNE adduct were readily apparent between the
groups of young mice (Figure 1A–D). Specifically, quantification
revealed neuronal densities of the HNE adduct were significantly
increased in the hippocampus of hAPP transgenic mice with
reduced Sod2 activity (hAPP/Sod2
+/2), but not in hAPP
transgenic mice with normal Sod2 activity (hAPP/Sod2
+/+), or
in Sod2
+/+ and Sod2
+/2 controls. However, HNE staining in mice
without hAPP was unaffected by the ablation of one Sod2 allele
(Figure 1E). Notably, neither hAPP expression alone (compare
Sod2
+/+ mice to hAPP/Sod2
+/+ mice) nor Sod2 reduction alone
(compare Sod2
+/+ to Sod2
+/2 mice) was sufficient to increase
neuronal HNE accumulation in young mice.
Upon qualitative assessment, levels of neuronal HO-1 in the
young mice (5–7 months of age) appeared higher in hippocampal
neurons of mice with ablation of one Sod2 allele, irrespective of
hAPP expression (Figure 2A–D). Quantification, however, re-
vealed only a slight increase in neuronal staining in these young
mice with the Sod2
+/2 mutation (Figure 2E) that did not reach
significance.
Unexpectedly, the results obtained for the older mice (25–30
months of age) contrasted with the results from the younger mice.
For example, neuronal HNE (Figure 3A) and HO-1 (Figure 3B)
staining in old mice revealed no significant differences between the
groups. Whereas the levels of both HNE and HO-1 tended to
Figure 1. Sod2 reduction, in synergy with hAPP/Ab expression,
results in increased levels of the lipid peroxidation product
HNE, in young (5–7 month-old) mice. Pyramidal neurons in the CA1
region of the hippocampus exhibit similar levels of HNE immunostain-
ing in the hAPP-/Sod2
+/+ (A), hAPP-/Sod2
+/2 (B), and the hAPP+/Sod2
+/+
(C) mice, whereas the hAPP+/Sod2
+/2 mice exhibit increased levels of
HNE (D). Quantification of the intensity of the neuronal HNE levels using
densitometric analysis reveals the hAPP+/Sod2
+/2 mice have signifi-
cantly higher levels of neuronal HNE adducts as compared to hAPP+/
Sod2
+/+, as well as the hAPP-/Sod2
+/+, hAPP-/Sod2
+/2 mice (E). Bars
represent mean + SEM, n=527 per group *p,0.05, **p,0.01 by one-
way ANOVA + Tukey Kramer post hoc analysis. ***p,0.05 by a one-
tailed student’s t-test.
doi:10.1371/journal.pone.0028033.g001
Reduced Sod2 in Disease Progression of AD Mice
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levels of these oxidative damage markers with the ablation of one
Sod2 allele at this age in the pyramidal neurons.
Since previous studies using these mice documented changes in
gliosis in old animals, we measured HNE and HO-1 levels in glial
cells. In Sod2
+/+ mice minimal astrocytosis was detected with an
antibodies to glial fibrillary acidic protein (GFAP), HNE, and HO-1
(data not shown). In old mice that lack mutant hAPP expression
there was moderate levels of astrocytosis in Sod2
+/2. Consistent
with previous results [15], the greater levels of astrocytosis in old
hAPP transgenic mice was lessened by Sod2 reduction. These
astrocytes also contained significant levels of HNE (Figure 4A) and
HO-1 (Figure 4B). High magnification images of the double-label
fluorescent microscopy confirmed that many of the cells with
accumulated oxidative damage are in fact astrocytes containing
GFAP. In young mice, astrocytosis was minimal as indicated by low
GFAPexpressionandnosignificantAb deposition(datanotshown).
Discussion
Oxidative stress emanating from the mitochondria has been
proposed to be a key pathogenic trigger in the progression of the
neuronal deficits that characterize AD. Moreover, the activity of
Sod2 has been reported to be reduced in AD brains [21]. In
support of this hypothesis, previous studies in hAPP transgenic
mice have shown that the reduction of Sod2 activity accelerates
the onset of AD-related behavioral deficits, alters amyloid
deposition, worsens the severity of synaptic density deficits and
neuritic dystrophy, enhances microgliosis and increases the activity
of the redox-sensitive transcription factor NFkB in the brains of
these mice. Overt increase in oxidative damage resulting from the
Sod2 reduction, however, was not initially detected in these mice
using traditional biochemical methods, which suggests that the
oxidative damage might be specific and/or focal. Furthermore,
since aging hAPP transgenic mice undergo further oxidative
changes and also exhibit a myriad of possible compensatory
mechanisms that might mask the effects of the Sod2 mutation, we
hypothesized that it is an earlier event of oxidative stress in the
hAPP/Sod2
+/2 mice that likely contributes to the pathology and
behavioral changes seen in this model.
To address this question, we assessed the levels of two widely
accepted and sensitive measures of oxidative damage, the lipid
Figure 2. Neuronal HO-1 immunostaining in the pyramidal
cells of the hippocampus of young (5–7 month-old) mice (A–D).
Densitometric quantitation demonstrates that HO-1 levels tend to be
higher in Sod2
+/2 and hAPP/Sod2
+/2 mice relative to mice with normal
Sod2 levels (Sod
+/+ and hAPP/Sod2
+/+) (E). Bars represent the mean +
SEM, n=527 per group.
doi:10.1371/journal.pone.0028033.g002
Figure 3. Immunostaining and densitometric quantification of HNE(A) and HO-1 (B) in pyramidal neurons in old (25–30 month-old)
mice shows that these oxidative stress markers tend to increase slightly with APP/Ab expression, although levels are not affected
by reduction of Sod2 activity. Bars represent the mean + SEM, n=527 per group.
doi:10.1371/journal.pone.0028033.g003
Reduced Sod2 in Disease Progression of AD Mice
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both young (5–7 month old) and old mice (25–30 month old). We
showed that in the hippocampus neuronal HNE levels were
increased dramatically in young hAPP transgenic mice with
reduced Sod2 activity. This result strongly suggests a possible
synergistic effect of decreased Sod2 activity and mutant hAPP/Ab
expression, yielding significantly increased oxidative damage in
neurons of young mice. Importantly, since no amyloid plaque
deposition was found in young mice, this result indicates that the
increase of oxidative stress at this age is Ab plaque independent
but dependent on Sod2 activity.
Chronic mitochondrial oxidative stress impairs mitochondrial
function, including oxidative phosphorylation [14], that can, in
turn, cause neuronal energy (ATP) deficits, negatively impact
endogenous cellular repair systems [22], inhibit axonal transport
[23], impair synaptic transmission [24,25] and further increase
reactive oxygen species production [26]. Mitochondrial dysfunc-
tion and oxidative stress occur early in all major neurodegener-
ative diseases, and there is strong evidence that this dysfunction
has a causal role in pathogenesis [27]. Our study supports the
conclusion that hAPP/Sod2
+/2 mice are more susceptible at an
early age to the accumulation of oxidative damage (HNE) which
Figure 4. High magnification images of the double immunofluorescence staining in the hippocampus of Sod2
+/2, hAPP/Sod2
+/+,
and hAPP/Sod2
+/2 mice at 25–30 months of age using antibodies against GFAP (Green fluorescence), HNE (Red fluorescence in A),
and HO-1 (Red fluorescence in B). In Sod2
+/2 mice there is a moderate level of astrocytic (GFAP) staining, and moderate levels of HNE (A) or HO-1
(B) localized to glial cells (Merged images). In hAPP/Sod2
+/+ and hAPP/Sod2
+/2 mice there is extensive plaque formation (Asterisk), striking increases
in levels of glial HNE(A), and HO-1 (B) relative to mice without hAPP/Ab expression. The magnification is 206.
doi:10.1371/journal.pone.0028033.g004
Reduced Sod2 in Disease Progression of AD Mice
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relative to hAPP mice with normal Sod2 activity [15].
Another oxidative stress marker, HO-1 induction, was subtly
increased by the Sod2
+/2 mutation, irrespective of hAPP/Ab
expression. The HO-1 immunoreactivity was intense in all animals,
which may account for the inability to differentiate between hAPP-
and hAPP+ pathology in different genotypes. Thus, in this study,
HNE proved to be a more sensitive marker for oxidative damage in
young hAPP/Sod2
+/2 mice and suggests that lipid peroxidation is
an acutely sensitive measure of oxidative damage in hAPP
transgenic mice. These results are consistent with studies in humans
in which lipid peroxidation products such as HNE, isoprostanes and
neuroprostanes have proven to be reliable biomarkers of AD [28–
30]. Overall, our current and previous data showing that the
reduction of Sod2 activity in younger mice accelerated oxidative
damage and hAPP/Ab-related pathology supports the hypothesis
that decreased Sod2 activity (and hence, increased O2
N2) contrib-
utes to neuronal deterioration and impairment in AD.
In older mice in which Ab deposition is apparent, Sod2
reduction did not significantly impact the oxidative damage that
appears to be occurring as a result of hAPP/Ab expression,
implying that effect of Sod2 reduction on oxidative damage is
saturated by a hAPP/Ab-mediated pathogenic mechanism that
occurs in the old mice. Alternately, it is interesting to note that an
increase in Ab deposition in AD patients brain is inversely
correlated with neuronal oxidative damage measured by the level
of 8-hydroxyguanosine, a major product of nucleic acid oxidation
[31]. Therefore, although the mechanism is still unclear, it is
tempting to propose that the accumulation of Ab might reduce or
hold steady the level of oxidative damage resulting from Sod2
reduction and consequently result in similar total levels of
oxidative damage in both hAPP/Sod2
+/+ and hAPP/Sod2
+/2
brains. In fact, it is likely that other compensatory mechanisms in
the brain may be upregulated with age and pathological
progression in AD and other neurodegenerative diseases.
Another interesting and important finding is the increase of
oxidative stress in the astrocytes of old mice. The oxidative stress
accumulated within astrocytes is correlated with not only APP/Ab
but with Sod2 reduction, suggesting that the combination of Sod2
reduction and APP/Ab expression augments oxidative stress in
astrocytes although its mechanism and pathological implication
remain to be elucidated. However, it might be possible that
oxidative stress causes astrocytic damage, leading to impaired
function including those functions that support neurons [32], and
ultimately contributing to the development of AD pathology. In
support of this notion, increased oxidative stress and DNA damage
in astrocytes in AD has been reported [33,34].
Our study provides strong support that neurons are the target of
the oxidative insult caused by the partial reduction in the main
mitochondrial superoxide scavenger Sod2, which accelerates the
onset of mutant APP-dependent behavioral abnormalities in J20 mice
[15] that are apparent even at 6–7 months of age [35]. Although the
precise mechanisms by which Sod2 reduction promotes Ab-induced
neuronal deficits remains to be determined, our study suggests that
reduction in the mitochondrial superoxide scavenger leads to the
degeneration of neuronal integrity in the early stage of the disease.
Supporting this hypothesis, the overexpression of Sod2 improved the
cognitive functions and reduced Ab accumulation in mutant hAPP
transgenic mice [36]. Thus, retaining full activity of mitochondrial
antioxidant defenses may be critical in preventing the early onset of
AD symptoms whereas bolstering mitochondrial antioxidant poten-
tial and overall function may halt the progression of AD.
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